Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
AVBP
#2111
ArriVent BioPharma, Inc. Common Stock
22.9
7
+0.22%
Sector:
Base:
Profit Currency:
Daily Range
Year Range
Daily Change
+0.22%
Monthly Change
-1.20%
6 month change
+19.57%
Year Change
-4.01%
Previous Close
22.9
2
Open
22.9
3
Bid
Ask
Low
22.9
3
High
22.9
7
Volume
76
Markets
US Stock Market
Healthcare
AVBP
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Value
2024
TTM
Dividends per share
—
—
Dividend yield %
—
—
Payout ratio %
—
—
News
ArriVent stock rating reiterated as Overweight by Cantor Fitzgerald
Oppenheimer reiterates Outperform rating on ArriVent BioPharma stock
ArriVent BioPharma (AVBP): Its Leading Asset, Furmonertinib, Supports A Cautious Buy
ArriVent BioPharma: A De-Risked Binary With Near-Term Catalysts (NASDAQ:AVBP)
Cantor Fitzgerald initiates ArriVent BioPharma stock with Overweight rating
ArriVent doses first patient in pivotal phase 3 trial for lung cancer drug
ArriVent BioPharma stock initiated with Buy rating at BTIG on oncology potential
ArriVent BioPharma stock initiated with Buy rating at Truist on lung cancer drug
ArriVent BioPharma stock price target raised to $47 from $32 at Clear Street
ArriVent BioPharma’s 32% decline validates InvestingPro’s overvaluation warning
ArriVent reports 16-month PFS for lung cancer drug firmonertinib
H.C. Wainwright raises ArriVent BioPharma stock price target to $42 on NSCLC drug potential